U.S. Markets closed
  • S&P Futures

    3,412.75
    -19.75 (-0.58%)
     
  • Dow Futures

    27,972.00
    -162.00 (-0.58%)
     
  • Nasdaq Futures

    11,628.25
    -63.00 (-0.54%)
     
  • Russell 2000 Futures

    1,594.70
    -8.40 (-0.52%)
     
  • Crude Oil

    39.79
    -0.24 (-0.60%)
     
  • Gold

    1,920.30
    -9.20 (-0.48%)
     
  • Silver

    25.02
    -0.22 (-0.88%)
     
  • EUR/USD

    1.1851
    -0.0015 (-0.1304%)
     
  • 10-Yr Bond

    0.8160
    +0.0190 (+2.38%)
     
  • Vix

    28.65
    -0.70 (-2.39%)
     
  • GBP/USD

    1.3138
    -0.0005 (-0.0394%)
     
  • USD/JPY

    104.6480
    +0.0880 (+0.0842%)
     
  • BTC-USD

    12,875.07
    +1,818.06 (+16.44%)
     
  • CMC Crypto 200

    257.92
    +13.03 (+5.32%)
     
  • FTSE 100

    5,776.50
    -112.72 (-1.91%)
     
  • Nikkei 225

    23,504.03
    -62.97 (-0.27%)
     

We Think ARCA biopharma (NASDAQ:ABIO) Can Afford To Drive Business Growth

Simply Wall St
·4 mins read

We can readily understand why investors are attracted to unprofitable companies. For example, although software-as-a-service business Salesforce.com lost money for years while it grew recurring revenue, if you held shares since 2005, you'd have done very well indeed. Nonetheless, only a fool would ignore the risk that a loss making company burns through its cash too quickly.

So should ARCA biopharma (NASDAQ:ABIO) shareholders be worried about its cash burn? In this report, we will consider the company's annual negative free cash flow, henceforth referring to it as the 'cash burn'. Let's start with an examination of the business' cash, relative to its cash burn.

See our latest analysis for ARCA biopharma

How Long Is ARCA biopharma's Cash Runway?

A cash runway is defined as the length of time it would take a company to run out of money if it kept spending at its current rate of cash burn. When ARCA biopharma last reported its balance sheet in June 2020, it had zero debt and cash worth US$11m. Looking at the last year, the company burnt through US$4.8m. Therefore, from June 2020 it had 2.3 years of cash runway. Arguably, that's a prudent and sensible length of runway to have. Depicted below, you can see how its cash holdings have changed over time.

debt-equity-history-analysis
debt-equity-history-analysis

How Is ARCA biopharma's Cash Burn Changing Over Time?

Because ARCA biopharma isn't currently generating revenue, we consider it an early-stage business. Nonetheless, we can still examine its cash burn trajectory as part of our assessment of its cash burn situation. With cash burn dropping by 16% it seems management feel the company is spending enough to advance its business plans at an appropriate pace. While the past is always worth studying, it is the future that matters most of all. For that reason, it makes a lot of sense to take a look at our analyst forecasts for the company.

Can ARCA biopharma Raise More Cash Easily?

While ARCA biopharma is showing a solid reduction in its cash burn, it's still worth considering how easily it could raise more cash, even just to fuel faster growth. Generally speaking, a listed business can raise new cash through issuing shares or taking on debt. Commonly, a business will sell new shares in itself to raise cash and drive growth. By comparing a company's annual cash burn to its total market capitalisation, we can estimate roughly how many shares it would have to issue in order to run the company for another year (at the same burn rate).

Since it has a market capitalisation of US$35m, ARCA biopharma's US$4.8m in cash burn equates to about 14% of its market value. Given that situation, it's fair to say the company wouldn't have much trouble raising more cash for growth, but shareholders would be somewhat diluted.

How Risky Is ARCA biopharma's Cash Burn Situation?

ARCA biopharma appears to be in pretty good health when it comes to its cash burn situation. One the one hand we have its solid cash burn relative to its market cap, while on the other it can also boast very strong cash runway. Considering all the factors discussed in this article, we're not overly concerned about the company's cash burn, although we do think shareholders should keep an eye on how it develops. On another note, we conducted an in-depth investigation of the company, and identified 5 warning signs for ARCA biopharma (2 are significant!) that you should be aware of before investing here.

Of course ARCA biopharma may not be the best stock to buy. So you may wish to see this free collection of companies boasting high return on equity, or this list of stocks that insiders are buying.

This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com.